OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have received an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $17.5714.

A number of analysts recently weighed in on OPRX shares. B. Riley Financial reissued a “buy” rating and issued a $11.00 price target (down from $28.00) on shares of OptimizeRx in a report on Friday. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Stifel Nicolaus lowered their target price on OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday. Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Finally, Roth Mkm dropped their target price on OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Friday.

Key Headlines Impacting OptimizeRx

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in OptimizeRx by 15.0% in the third quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock valued at $21,712,000 after buying an additional 138,224 shares during the period. Royce & Associates LP grew its holdings in OptimizeRx by 0.7% during the 4th quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock worth $8,362,000 after acquiring an additional 4,700 shares during the period. Kennedy Capital Management LLC raised its position in shares of OptimizeRx by 42.8% during the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock valued at $13,836,000 after acquiring an additional 202,446 shares during the last quarter. Rice Hall James & Associates LLC raised its position in shares of OptimizeRx by 8.2% during the 4th quarter. Rice Hall James & Associates LLC now owns 590,674 shares of the company’s stock valued at $7,242,000 after acquiring an additional 44,858 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of OptimizeRx by 0.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after purchasing an additional 2,188 shares during the period. 76.47% of the stock is owned by institutional investors.

OptimizeRx Stock Down 10.5%

Shares of NASDAQ:OPRX opened at $6.74 on Wednesday. The company has a quick ratio of 3.05, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. The firm has a market cap of $125.63 million, a P/E ratio of 25.92 and a beta of 1.21. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The company’s 50-day moving average price is $10.52 and its two-hundred day moving average price is $14.72.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%. As a group, research analysts forecast that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx declared that its Board of Directors has initiated a stock repurchase plan on Thursday, March 5th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.